Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Social support, disclosure, and use of antiretroviral therapy.

Waddell EN, Messeri PA.

AIDS Behav. 2006 May;10(3):263-72.

PMID:
16496089
2.

Social support and medication adherence in HIV disease in KwaZulu-Natal, South Africa.

Ncama BP, McInerney PA, Bhengu BR, Corless IB, Wantland DJ, Nicholas PK, McGibbon CA, Davis SM.

Int J Nurs Stud. 2008 Dec;45(12):1757-63. doi: 10.1016/j.ijnurstu.2008.06.006.

PMID:
18653188
3.

Effect of antiretroviral treatment and counselling on disclosure of HIV-serostatus in Johannesburg, South Africa.

Skogmar S, Shakely D, Lans M, Danell J, Andersson R, Tshandu N, Odén A, Roberts S, Francois Venter WD.

AIDS Care. 2006 Oct;18(7):725-30.

PMID:
16971281
5.

Social relationships, stigma and adherence to antiretroviral therapy for HIV/AIDS.

Ware NC, Wyatt MA, Tugenberg T.

AIDS Care. 2006 Nov;18(8):904-10.

PMID:
17012079
6.

Once and future HIV treatment: a comparison of clinic and community groups.

Rothenberg R, Campos PE, del Rio C, Johnson W, Arriola KJ, Brown M.

Int J STD AIDS. 2003 Jul;14(7):438-47.

PMID:
12869222
7.

Disclosure of HIV among black African men and women attending a London HIV clinic.

Calin T, Green J, Hetherton J, Brook G.

AIDS Care. 2007 Mar;19(3):385-91.

PMID:
17453574
8.
9.

Microsocial environmental influences on highly active antiretroviral therapy outcomes among active injection drug users: the role of informal caregiving and household factors.

Knowlton AR, Arnsten JH, Gourevitch MN, Eldred L, Wilkinson JD, Rose CD, Buchanan A, Purcell DW; INSPIRE Study Team..

J Acquir Immune Defic Syndr. 2007 Nov 1;46 Suppl 2:S110-9. doi: 10.1097/QAI.0b013e31815767f8.

PMID:
18089980
11.

Individual, interpersonal, and structural correlates of effective HAART use among urban active injection drug users.

Knowlton A, Arnsten J, Eldred L, Wilkinson J, Gourevitch M, Shade S, Dowling K, Purcell D; INSPIRE Team..

J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):486-92.

PMID:
16652058
12.

Depression, social support and adherence to highly active antiretroviral therapy in people living with HIV/AIDS.

Gibbie T, Hay M, Hutchison CW, Mijch A.

Sex Health. 2007 Dec;4(4):227-32.

PMID:
18082064
13.
14.

The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART.

Castor D, Vlahov D, Hoover DR, Berkman A, Wu YF, Zeller B, Brechtl J, Hammer SM.

J Med Virol. 2009 Aug;81(8):1323-35. doi: 10.1002/jmv.21500.

PMID:
19551816
15.

Successive switching of antiretroviral therapy is associated with high psychological and physical burden.

Sherr L, Lampe F, Norwood S, Leake-Date H, Fisher M, Edwards S, Arthur G, Anderson J, Zetler S, Johnson M, Harding R.

Int J STD AIDS. 2007 Oct;18(10):700-4.

PMID:
17945049
16.

Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era.

Madeddu G, Porqueddu EM, Cambosu F, Saba F, Fois AG, Pirina P, Mura MS.

Infection. 2008 Jun;36(3):231-6. doi: 10.1007/s15010-007-7162-0.

PMID:
18463787
17.

An adherence typology: coping, quality of life, and physical symptoms of people living with HIV/AIDS and their adherence to antiretroviral treatment.

Bader A, Kremer H, Erlich-Trungenberger I, Rojas R, Lohmann M, Deobald O, Lochmann R, Altmeyer P, Brockmeyer N.

Med Sci Monit. 2006 Dec;12(12):CR493-500.

PMID:
17136004
18.

Factors associated with HIV/AIDS diagnostic disclosure to HIV infected children receiving HAART: a multi-center study in Addis Ababa, Ethiopia.

Biadgilign S, Deribew A, Amberbir A, Escudero HR, Deribe K.

PLoS One. 2011 Mar 21;6(3):e17572. doi: 10.1371/journal.pone.0017572.

19.
20.

Predictors for lower quality of life in the HAART era among HIV-infected men.

Liu C, Johnson L, Ostrow D, Silvestre A, Visscher B, Jacobson LP.

J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):470-7.

PMID:
16810114
Items per page

Supplemental Content

Support Center